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by offering training opportunities, harmonized methods, tools, and 
data resources.
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Summary: In 1970, the World Health Organization (WHO) pub-
lished its well-known manifesto on clinical pharmacology, which for 
many years was the gold standard of the discipline.1 However, for 
the last 10 years or so it has been clearly in need of updating. This 
was finally achieved in 2012 after 3 to 4 years of work by the above-
named editors and a team of distinguished clinical pharmacologists 
from around the world. Their work was supported not only by the 
WHO but also by the Council for International Organizations of 
Medical Sciences (CIOMS) and the International Union of Basic and 
Clinical Pharmacology (IUPHAR). The document covers a number 
of different facets of the work of clinical pharmacologists but in par-
ticular highlights the role of clinical pharmacology in the delivery of 
health care.2 A recent questionnaire study in 31 European countries3 
has identified the weakness of clinical pharmacology in health care, 
particularly in its failure to provide clinical pharmacologic services 
that will promote the rational use of medicines (RUM).
The main chapter on “The Clinical Pharmacologist in Patient 
Care” covers a number of different ways in which the discipline 
can help deliver better patient care. The importance of the various 
modalities discussed will depend on the way in which health care is 
delivered in different countries. In a few countries, the clinical phar-
macologist (CP) will be directly involved in the care of both inpatients 
and outpatients. However, in the majority of countries, the CP will be 
more involved indirectly in patient care. In all countries, the CP will 
be closely involved in the critical evaluation of new and old therapies; 
in the work of Drug and Therapeutic committees, both national and 
local; and in services such as drug information, pharmacovigilance, 
and drug utilization studies. In addition, the CP in many countries is 
directly involved in therapeutic drug monitoring (TDM) and phar-
macogenetic services aiming to facilitate personalized medicine. The 
overall purpose of the manifesto is to strengthen the role of clinical 
pharmacology in achieving RUM, and this is the focus of the last 
chapter in the manifesto.
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Summary: The thalidomide disaster detected in 1961 initiated the 
first systematic international effort to address medicine safety issues 
at the global level. The Sixteenth World Health Assembly (1963) 
adopted a resolution (WHA 16.36) that reaffirmed the need for early 
action in regard to rapid dissemination of information on adverse 
reactions due to medicines and led to the WHO Programme for 
International Drug Monitoring. Under this program, systems have 
been developed in member states for the collection of individual 
case safety reports (ICSRs) and their evaluation. The reports are 
held in a central database, managed and maintained by the WHO 
Collaborating Centre for International Drug Monitoring, the Uppsala 
Monitoring Centre (UMC) in Sweden. The work of the UMC, with 
policy directives from WHO, serves the important function of con-
tributing to the work of national drug regulatory authorities and 
other relevant stakeholders, by improving the knowledge of safety 
profiles of medicines. As of June 2013, there are 144 countries partici-
pating in the program, with access to a WHO database containing > 8 
million ICSRs. This presentation will trace the growth of the program 
these last 40 years, address gaps in pharmacovigilance at national 
and international levels, determine trends and the most urgent PV 
priorities in defined settings, and identify the broad elements of a 
pharmacovigilance strategy that will promote quality health care 
and assure patient safety.
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Summary: Drug-induced liver injury (DILI) represents a significant 
cause of patient morbidity and mortality and is a major contributor 
to attrition in drug development. Prediction of clinical DILI remains 
difficult, particularly in cases characterized by marked interindividual 
variation. A lack of sensitivity, specificity, and an indirect mechanistic 
basis of currently used markers of hepatic injury remains a factor 
for the delayed identification of DILI. There is a need to discover, 
develop, and validate new biomarkers to better inform the medicinal 
chemist and the clinician. The ideal biomarker is 1 that is mechanism-
based, organ (cell) selective, and that can be used in both the clinic 
and laboratory models. Traditional biomarkers of DILI include leak-
age markers of cell death and markers of hepatic function. Preclinical 
DILI biomarker identification and validation have been focused on 
molecular biomarkers such as cytokeratin-18, high mobility group 
box-1 protein, and micoRNA-122, which are more informative with 
respect to chemical stress, adaptation, and mechanisms of cellular 
damage. Recent reports have shown that these hold translational 
application to inform both the sensitive identification of DILI and 
also its mechanistic basis in man. Furthermore, a number of these 
biomarkers provide enhanced prognostic information during clinical 
acetaminophen overdose. The integrated use of these and other mark-
ers will be discussed from a backdrop of imperfect current standards 
